Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2021-05-27 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Second Price Monitoring Extn
Regulatory Filings Classification · 98% confidence The document is very short (1928 chars) and contains the header 'RNS Number' and mentions 'RNS, the news service of the London Stock Exchange' and 'Financial Conduct Authority'. It announces a 'Second Price Monitoring Extension' related to trading activity, which is a specific, time-sensitive regulatory market announcement. This type of general regulatory announcement that doesn't fit into the specific financial reporting categories (like 10-K, ER, IR) is best classified as a general Regulatory Filing, which corresponds to the RNS code.
2021-05-27 English
Price Monitoring Extension
Regulatory Filings Classification · 98% confidence The document is very short (1911 characters) and contains the header 'RNS Number'. It announces a 'Price Monitoring Extension' related to trading on the London Stock Exchange. It explicitly states that the information is provided by RNS, the news service of the London Stock Exchange, which is approved as a Primary Information Provider. This is a general regulatory announcement that does not fit into specific financial reporting categories like 10-K, ER, or IR. Therefore, it falls under the general regulatory announcement category.
2021-05-27 English
ASTRAZENECA PRICES A EUR800M BOND OFFERING
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. The content primarily announces the pricing of a EUR800 million bond offering, detailing the terms, use of proceeds, and related information. It does not contain comprehensive financial statements or detailed financial analysis typical of an interim or annual report. The document is relatively short (4151 characters) and serves as an announcement of a financing event. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2021-05-27 English
AstraZeneca prices a EUR800m bond offering
Capital/Financing Update Classification · 98% confidence The document is a short announcement (3642 characters) released via RNS (Regulatory News Service) of the London Stock Exchange. The content explicitly details the pricing and issuance of €800m in fixed-rate notes (bonds) intended to fund a portion of the Alexion Acquisition. This activity directly relates to the company's financing structure and capital raising efforts. Based on the definitions, 'Capital/Financing Update' (CAP) is the most appropriate classification for announcing a bond offering. Although it is an RNS release, the specific nature of the content (pricing a major bond offering) makes CAP more precise than the general fallback RNS.
2021-05-27 English
425 Filing
Merger & Acquisition Classification · 95% confidence The document is filed by AstraZeneca PLC pursuant to Rule 425 under the U.S. Securities Act of 1933, which is a rule related to communications in connection with mergers and acquisitions. The text discusses the proposed acquisition of Alexion Pharmaceuticals, including references to a Form F-4 registration statement, proxy statement/prospectus filings, and solicitation of proxies. It also includes forward-looking statements typical of merger communications. The document is not a full merger proxy statement or registration statement itself but a communication related to the acquisition process. Rule 425 filings are specifically used for merger-related communications and are classified under Merger & Acquisition (MA). The document length (9010 characters) and content confirm it is a substantive communication about the acquisition, not merely an announcement or a proxy solicitation material. Therefore, the appropriate classification is Merger & Acquisition (MA).
2021-05-27 English
ASTRAZENECA PRICES A $7BN BOND OFFERING
Capital/Financing Update Classification · 100% confidence The document is a Form 6-K filing by AstraZeneca PLC, which is a report of a foreign issuer submitted to the SEC. The content details the pricing of a $7 billion bond offering, including the terms of the notes and the intended use of proceeds. It is an announcement of a financing transaction, specifically a bond issuance. The document does not contain comprehensive financial statements or detailed financial performance data, but rather focuses on the capital raising activity. Therefore, it fits the category of Capital/Financing Update (CAP). The document length (6186 characters) and content confirm it is a full announcement, not just a brief notice or a report publication announcement.
2021-05-26 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.